IR@PKUHSC  > 北京大学第一临床医学院  > 肾脏内科
学科主题临床医学
Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial
Liu, Li-Jun; Lv, Ji-Cheng; Shi, Su-Fang; Chen, Yu-Qing; Zhang, Hong; Wang, Hai-Yan
关键词Immunoglobulin a (Iga) Nephropathy Proteinuria Calcitriol Renin-angiotensin System
刊名AMERICAN JOURNAL OF KIDNEY DISEASES
2012
DOI10.1053/j.ajkd.2011.09.014
59期:1页:67-74
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Urology & Nephrology
研究领域[WOS]Urology & Nephrology
关键词[WOS]CHRONIC KIDNEY-DISEASE ; IMMUNOGLOBULIN-A NEPHROPATHY ; VITAMIN-D ANALOG ; TERM-FOLLOW-UP ; 1,25-DIHYDROXYVITAMIN D-3 ; COMBINATION THERAPY ; RENAL INFLAMMATION ; NATURAL-HISTORY ; PARICALCITOL ; CHINESE
英文摘要

Background: Vitamin D has shown efficacy in the reduction of proteinuria in patients with chronic kidney disease. This study aimed to determine the effect of calcitriol on urinary protein excretion in patients with immunoglobulin A (IgA) nephropathy.

Study Design: Open-label, non-placebo-controlled, randomized study.

Setting & Participants: 50 patients with IgA nephropathy were enrolled. The main criterion for inclusion was urinary protein excretion >0.8 g/d after renin-angiotensin system-inhibitor treatment for at least 3 months.

Intervention: Patients were randomly assigned (1: 1) to receive 2 doses (0.5 mu g) of calcitriol per week or no treatment for 48 weeks.

Outcomes: The primary end point was to compare change in 24-hour urinary protein excretion from baseline to last measurement during treatment.

Measurements: Every 8 weeks, there was measurement of 24-hour urinary protein excretion, serum calcium, serum phosphorus, serum creatinine, and intact parathyroid hormone.

Results: Measurement of the primary end point showed changes in urinary protein excretion of +21% (from 1.29 to 1.58 g/24 h; 95% CI, -9% to +52%) in the control group and -19% (from 1.60 to 1.30 g/24 h; 95% CI, -42% to +4%) in the calcitriol-treated group. There was a significant decrease in proteinuria in the calcitriol-treated group compared with the control group (difference between groups, 41%; 95% CI, 5%-79%; P = 0.03). The secondary end point of achieving at least a 15% decrease in proteinuria was attained by 7 of 24 (29%) controls and 17 of 26 (65%) of those treated with calcitriol (P = 0.02). No significant differences were observed in decrease in estimated glomerular filtration rate and change in blood pressure between the 2 groups. The incidence of recorded adverse events was similar between the 2 groups.

Limitations: Small and non-placebo-controlled study.

Conclusions: The addition of calcitriol to a renin-angiotensin system inhibitor resulted in a safe decrease in proteinuria in patients with IgA nephropathy. Am J Kidney Dis. 59(1): 67-74. (C) 2011 by the National Kidney Foundation, Inc.

语种英语
WOS记录号WOS:000298153600014
引用统计
被引频次:46[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51609
专题北京大学第一临床医学院_肾脏内科
作者单位Peking Univ, Div Renal, Peking Univ Hosp 1, Inst Nephrol,Key Lab Renal Dis,Minist Hlth China, Beijing 100034, Peoples R China
推荐引用方式
GB/T 7714
Liu, Li-Jun,Lv, Ji-Cheng,Shi, Su-Fang,et al. Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial[J]. AMERICAN JOURNAL OF KIDNEY DISEASES,2012,59(1):67-74.
APA Liu, Li-Jun,Lv, Ji-Cheng,Shi, Su-Fang,Chen, Yu-Qing,Zhang, Hong,&Wang, Hai-Yan.(2012).Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial.AMERICAN JOURNAL OF KIDNEY DISEASES,59(1),67-74.
MLA Liu, Li-Jun,et al."Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial".AMERICAN JOURNAL OF KIDNEY DISEASES 59.1(2012):67-74.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Li-Jun]的文章
[Lv, Ji-Cheng]的文章
[Shi, Su-Fang]的文章
百度学术
百度学术中相似的文章
[Liu, Li-Jun]的文章
[Lv, Ji-Cheng]的文章
[Shi, Su-Fang]的文章
必应学术
必应学术中相似的文章
[Liu, Li-Jun]的文章
[Lv, Ji-Cheng]的文章
[Shi, Su-Fang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。